FORM PTO-1449 (Modified)

LIST OF PATENTS AND PUBLICATIONS FOR APPLICANT'S INFORMATION DISCLOSURE STATEMENT

ATTY.	DOCKET	NO.
18025	-1014	

SERIAL NO. 09/887,496

APPLICANT

Banerjee, Partha S.

FILING DATE June 22, 2001 GROUP 1617

U.S. PATENT DOCUMENTS

EXAMINER INITIAL		DOCUMENT NUMBER							DATE	NAME	CLASS	SUB CLASS	FILING DATE
MA	Α	0	0	2	4	6	4	1	09/27/01	Yang	424	46	04/02/01
1	В	0	0 ·	3	2	1	4	9	03/14/02	Kensey	514	1	04/24/01
	С	0	0	6	1	8	3	5	05/23/02	Kensey	514	1	04/09/01
	D	0	0	8	1	2	6	6	06/27/02	Woolfe et al.	424	46	08/14/01
	Е	0	0	9	9	0	1	3	07/25/02	Piccariello <i>et al.</i>	514	12	08/22/01
	F	0	1	0	3	2	6	0	08/01/02	Clarke <i>et al.</i>	514	630	08/15/01
	G	0	1	5	1	5	9	7	10/17/02	Banerjee <i>et al.</i>	514	629	07/22/01
	н	4	3	3	5	1	2	1	06/15/82	Phillipps et al.	424	241	02/13/81
	ı	4	9	9	2	4	7	4	02/12/91	Skidmore <i>et al.</i>	514	653	08/23/89
	J	5	1	2	6	3	7	5	06/30/92	Skidmore <i>et al.</i>	514	651	11/29/90
	К	5	2	2	5	4	4	5	07/06/93	Skidmore et al.	514	651	02/19/92
	L	5	2	7	0	3	0	5	12/14/93	Palmer	514	171	09/03/91
	М	5	2	9	0	8	1	5	03/01/94	Johnson et al.	514	651	11/25/91
	N	5	8	7	4	0	6	3	02/23/99	Briggner <i>et al.</i>	424	45	02/26/96
	0	5	9	8	0	9	4	9	11/09/99	Trofast	424	489	01/09/98
	Р	5	9	8	3	9	5	6	11/16/99	Trofast	141	1	01/09/98
	Q	6	0	3	0	6	0	4	02/29/00	Trofast	424	46	01/09/98
	R	6	2	8	7	5	4	0	09/11/01	Trofast	424	46	11/02/99
Mo	s	6	3	6	9	1	1	5	04/09/02	Ward	514	728	03/20/00

FOREIGN PATENT DOCUMENTS

			D	OCUM	IENT N	NUMBI	ER		DATE	COUNTRY	CLASS	SUB CLASS	Trans Yes	slation No
Mb	Т	0	0	0	6	1	2	1	02/10/00	PCT				X*
	U	0	0	0	7_	5	6	7	02/17/00	PCT				X*
NB	>	0	0	1	6	8	1	4	03/30/00	РСТ				

EXAMINER

MA

DATE CONSIDERED

05/15/00

EODM.	DTO	1//0	(Modified)
FURIN	P10-	1449	(ivioaiiiea)

LIST OF PATENTS AND PUBLICATIONS FOR APPLICANT'S INFORMATION DISCLOSURE STATEMENT

ATTY.	DOCKET	NO.
18025	-1014	

SERIAL NO. 09/887,496

APPLICANT Banerjee, Partha S.

FILING DATE June 22, 2001 GROUP 1617

FOREIGN PATENT DOCUMENTS

1/8			D	эсим	ENT N	IUMBE	ĒR		DATE	COUNTRY	CLASS	SUB CLASS	Trans Yes	slation No
1	w	0	0	2	8	9	7	9	05/25/00	PCT				X*
	Х	0	0	3	0	6	1	2	06/02/00	РСТ				
	Y	0	0	3	0	6	1	3	06/02/00	РСТ				
	Z	0	0	3	3	8	9	2	06/15/00	PCT				
	AA	0	0	4	7	2 ′	0	0	08/17/00	PCT				
	АВ	0	0	4	8	5	8	7	08/24/00	PCT				
	AC	0	0	5	1	5	9	1	08/08/00	PCT				
	AD	0	0	5	3	1	8	7	09/14/00	PCT				
	AE	0	0	5	3	1	8	8	09/14/00	PCT				
	AF	0	1	2	7	1	0	7	04/19/01	PCT				
	AG	0	1	2	2	9	5	6	04/05/01	PCT				X*
	АН	0	1	3	2	1	6	3	05/10/01	PCT				
•	Al	0	1	3	9	7	4	5	06/07/01	PCT				
	AJ	0	1	5	4	6	6	4	08/02/01	PCT				
	AK	0	1	7	0	1	9	8	09/27/01	PCT		-		
	AL	0	1	7	8	7	3	5	10/25/01	PCT				
	AM	0	1	7	8	7	4	5	10/25/01	PCT				
	AN	0	1	8	3	5	1	7	11/08/01	PCT			ļ	
	AO	0	1	8	5	1	3	7	11/15/01	PCT				
	AP	0	1	8	9	4	9	1	11/29/01	PCT				
	ΔQ	0	2	0	3	9	5	8	01/17/02	PCT				
	AR	0	2	0	7	6	7	2	01/31/02	PCT				
	AS	0	2	1	1	8	0	3	02/14/02	PCT				
	АТ	0	2	2	8	3	6	8	04/11/02	PCT			,	
W	AU	0	2	3	0	3	9	4	04/18/02	РСТ				

EXAMINER

VMI

DATE CONSIDERED

05/14/02

FORM PTO-1449 (Modified)

LIST OF PATENTS AND PUBLICATIONS FOR APPLICANT'S INFORMATION DISCLOSURE **STATEMENT**

ATTY.	DOCKET	NO.
18025	-1014	

SERIAL NO. 09/887,496

APPLICANT Banerjee, Partha S.

FILING DATE June 22, 2001 **GROUP** 1617

FOREIGN PATENT DOCUMENTS

				DO	эсим	ENT N	IUMBE	R		DATE	COUNTRY	CLASS	SUB CLASS	Trans Yes	slation No
-M	7	AV	0	2	3	4	2	3	7	05/02/02	PCT				
		AW	0	2	3	8	1	0	7	05/16/02	PCT				
		AX	0	2	4	3	8	0	6	06/06/02	PCT				
		AY	0	2	4	5	6	8	2	06/13/02	РСТ				
		ΑZ	0	2	4	9	6	1	6	06/27/02	РСТ				
		ВА	02	0	5	1	4	8	3	07/04/02	РСТ				
		BB	02	0	6	0	5	3	2	08/08/02	PCT				X*
		вс	02	0	6	0	5	3	3	08/08/02	PCT				X*
		BD	02	0	6	0	8	7	5	08/08/02	PCT		_		
		BE	02	0	6	0	8	9	6	08/08/02	PCT		. <u> </u>		
		BF	02	0	6	0	8	9	8	08/08/02	РСТ				
		BG	02	0	6	2	3	1	7	08/15/02	PCT				
		вн	02	0	8	3	1	1	3	10/24/02	РСТ				
		ВІ	1	1	5	7	6	8	9	11/28/01	EP (A1)				- <u>-</u>
		BJ	1	2	2	9	0	3	4	08/07/02	EP (A1)				
		вк	1	2	3	6	4	6	7	09/04/02	PCT				
		BL	19	5	4	1	6	8	9	05/15/96	DE				X*
		вм	19	8	3	5	3	4	6	02/10/00	DE				X*
		BN	9	3	1	1	7	7	3	06/24/93	PCT				
		во	9	5	0	5	8	0	5	03/02/95	PCT				
		ВР	9	6	1	8	3	8	4	06/20/96	PCT				
		BQ	9	6	1	9	1	9	8	06/27/96	PCT				
		BR	9	6	1	9	9	6	8	07/04/96	PCT				
		BS	9	6	3	2	0	9	5	10/17/96	PCT				
M		вт	9	8	0	5	3	0	2	02/12/98	PCT				

EXAMINER

DATE CONSIDERED 6 5/14/29

FORM PTO-1449 (Modified)	ATTY. DOCKET NO. 18025-1014	SERIAL NO. 09/887,496
LIST OF PATENTS AND PUBLICATIONS FOR APPLICANT'S INFORMATION DISCLOSURE	APPLICANT Banerjee, Partha S.	
STATEMENT	FILING DATE	GROUP

FOREIGN PATENT DOCUMENTS

			D	OCUM	IENT N	NUMBI	ER		DATE	COUNTRY	CLASS	SUB CLASS	Trans Yes	slation No
100	BU	9	8	1	5	2	8	0	04/16/98	PCT				
	BV	9	8	3	1	3	5	1	07/23/98	РСТ				
	BW	9	8	3	1	3	5	2	07/23/98	РСТ				
	вх	9	8	3	4	5	9	5	08/13/98	РСТ				X*
	BY	9	8	3	4	5	9	6	08/13/98	PCT				
	BZ	9	8	4	1	1	9	3	09/24/98	PCT				
	CA	9	9	0	0	1	3	4	01/07/99	PCT				
	СВ	9	9	1	5	1	8	2	04/01/99	PCT				
	СС	9	9	3	0	7	0	3	06/24/99	PCT				
	CD	9	9	4	0	9	3	9	08/19/99	PCT				
-	CE	9	9	4	8	4	7	6	09/30/99	PCT				
W	CF	9	9	6	1	0	0	3	12/02/99	PCT				

X* = English Language Derwent Abstract is provided.

OTHER ART (Including Author, Title, Date, Pertinent Pages, Etc.)

W	CG	Barnes, P.J., "Scientific rationale for inhaled combination therapywith long-acting θ_2 -agonists and corticosteroids," <i>Eur. Respir. J.</i> 182-191 (2002)
	СН	Campestrini <i>et al.</i> , "Automated and sensitive method for the determination of formoterol in human plasma by high-performance liquid chromatography and electrochemical detection," <i>Journal of Chromatography B</i> 704: 221-229 (1997)
	CI	Cazzola et al., "Long-Acting θ_2 -Agonists in the Treatment of Acute Exacerbations of COPD," Clin. Drug Invest. 22(6): 369-376 (2002)
	Cl	Derwent#010743444, WPI Acc No.:1996-240399/199625 for German Patent Application DE 19541689, "Medicament contg. ciclesonid and beta2-sympathomimetic for treating chromic obstructive respiratory disease,"
M	СК	Derwent#012030009, WPI Acc No.:1998-446919-199838 for PCT Patent Application WO 98/34595, "Pressurised liquid aerosol propellant for pharmaceutical inhalers-contains carbon dioxide and hydro-fluoroalkane; gives more consistent dosing and a better particle size spectrum,"

			<u> </u>
FX	ΔM	INFR	•

DATE CONSIDERED

105/14/00

FORM PTO-1449 (Modified)	ATTY. DOCKET NO. 18025-1014	SERIAL NO. 09/887,496
LIST OF PATENTS AND PUBLICATIONS FOR APPLICANT'S INFORMATION DISCLOSURE	APPLICANT Banerjee, Partha S.	
STATEMENT	FILING DATE June 22, 2001	GROUP 1617

OTHER ART (Including Author, Title, Date, Pertinent Pages, Etc.)

		THER ART (Including Author, Title, Date, Fertillett Fages, Ltc.)
M	CL	Derwent#013011051, WPI Acc No.:2000-182903/200016 for PCT Patent Application WO 00/06121, "Aerosol propellant comprising dinitrogen monoxide and hydrofluoroalkane and optionally containing a pharmaceutically active substance,"
	СМ	Derwent#013023586, WPI Acc No. 2000-195437/200017, for PCT Patent Application WO 00/07567 "Aerosol formulation for drug administration, containing small amount of cromoglycate or nedocromil salt as drug carrier, to improve dispersion stability and accuracy of dosing,"
	CN	Derwent#013024375, WPI Acc No.: 2000-196226/200018 for German Patent Application DE 19835346, "Two-part drug capsule for use in powder inhalers is formed from hydrophobic plastics, preferably high density polyethylene,"
	СО	Derwent#013227765, WPI Acc No. 2000-399639/200034, for PCT Patent Application, WO 00/28979 "Use of magnesium stearate for stabilization of dry powder inhalation formulations to improve resistance to moisture,"
	СР	Derwent#013790372, WPI Acc No.: 2001-274583/200129, for PCT Patent Application, WO 01/22956 "Drug combination of soft steroid and beta-2-adrenoceptor agonist, administered by inhalation for effective treatment of respiratory or allergic diseases, e.g. asthma,"
	ca	Derwent#014808338, WPI Acc No.:2002-629044/200268, for PCT Patent Application, WO 02/060533 "Medicament containing a betamimetic and an oxitropium salt useful for the treatment of respiratory disorders with reduced side effects,"
	CR	Derwent#014816787, WPI. Acc No.: 2002-637493/200269, for PCT Patent Application, WO 02/060532 "Medicament containing a betamimetic and an ipratropium salt useful for the treatment of respiratory disorders with reduced side effects,"
	cs	Eickelberg et al., "Ligand-independent Activation of the Glucocorticoid Receptor by θ_2 -Adrenergic Receptor Agonists in Primary Human Lung Fibroblasts and vascular Smooth Muscle Cells," The Journal of Biological Chemistry 274(2): 1005-1010 (1999)
	СТ	Farmer <i>et al.</i> , "6-Adrenergic agonists exert their "anti-inflammatory" effects in monocytic cells through the IrB/NF-rB pathway," <i>Am. J. Physiol. Lung. Cell. Mol. Physiol.</i> 279: 1675-682 (2000)
	CU	Greening et al., "Added salmeterol versus higher-dose corticosteroid in asthma patients with symptoms on existing inhaled corticosteroid," <i>The Lancet</i> 344: 219-224 (1994)
Mo	CV	Grootendorst <i>et al.</i> , "Effect of oral prednisolone on the bronchoprotective effect of formoterol in patients with persistent asthma," <i>Eur. Respir. J.</i> <u>17:</u> 374-379 (2001)

EXAMINER

MA

DATE CONSIDERED

05/14/00

FORM PTO-1449 (Modified)	ATTY. DOCKET NO. 18025-1014	SERIAL NO. 09/887,496
LIST OF PATENTS AND PUBLICATIONS FOR APPLICANT'S INFORMATION DISCLOSURE	APPLICANT Banerjee, Partha S.	
STATEMENT	FILING DATE June 22, 2001	GROUP 1617

OTHER ART (Including Author, Title, Date, Pertinent Pages, Etc.)

	_	There with American granter, that, butter, to the trades, butter,
M	cw	lda, Hisashi, "Pharmacology of Formoterol, (α RS)-3-formamido-4-hydroxy- α -[[[(α RS)- ρ -methoxy- α -methylphenethyl] amino] methyl] benzylalcohol fumarate dihydrate (BD 40A)," <i>Oyo Yakuri</i> 21(2): 201-210 (1981)
	сх	Ito <i>et al.</i> , "Glucocorticoid Receptor Recruitment of Histone Deacetylase 2 Inhibits Interleukin-16-Induced Histone H4 Acetylation on Lysines 8 and 12," Molecular and Cellular Biology <u>20(18):</u> 6892-6903 (2000)
	CY	Ito et al., "p65-activated Histone Acetyltransferase Activity Is Repressed by Glucocorticoids," <i>The Journal of Biological Chemistry</i> 276(32): 30208-30215 (2001)
	CZ	Korn <i>et al.</i> , "Effects of formoterol and budesonide on GM-CSF and IL-8 secretion by triggered human bronchial epithelial cells," <i>Eur. Respir. J.</i> 17: 1070-1077 (2001)
	DA	Lipworth <i>et al.</i> , "Effects of Treatment with Formoterol on Bronchoprotection against Methacholine," <i>Am. J. Med.</i> 104: 431-438 (1998)
	DB	Malolepszy <i>et al.</i> , "Safety of formoterol Turbuhaler™ at cumulative dose of 90µg in patients with acute bronchial obstruction," <i>Eur. Respir. J.</i> <u>18:</u> 928-934 (2001)
	DC	O'Connor, B.J., "Combination Therapy," <i>Pulmonary Pharmacology & Therapeutics</i> 11: 397-399 (1998)
	DD	Oddera <i>et al.</i> , "Salmeterol Enhances the Inhibitory Activity of Dexamethasone on Allergen-Induced Blood Mononuclear Cell Activation," <i>Respiration</i> 65: 199-204 (1998)
	DE	Package Insert for: ADVAIR™ DISKUS http://fb.a-files.net/PackageInsert/Advair.htm (acessed on 09/26/02) (Copyright, 1999 Glaxo Wellcome Inc.)
	DF	Palmqvist <i>et al.</i> , "Onset of Bronchodilation of Budesonide/Formoterol vs. Salmeterol/Fluticasone in Single Inhalers," <i>Pulmonary Pharmacology & Therapeutics</i> 14: 29-34 (2001)
	DG	Pang, L. and A.J. Knox, "Regulation of TNF- α -induced eotaxin release from cultured human airway smooth muscle cells by θ_2 -agonists and corticosteroids," <i>FASEB J.</i> 15: 261-269 (2001)
	DH	Pang, L. and A.J. Knox, "Synergistic Inhibition by θ_2 -Agonists and Corticosteroids on Tumor Necrosis Factor- α -Induced Interleukin-8 Release from Cultured Human Airway Smooth-Muscle Cells," <i>Am. J. Respir. Cell Mol. Biol.</i> 23: 79-85 (2000)
	DI	Pauwels et al., "Effect of Inhaled Formoterol and Budesonide on Exacerbations of Asthma," The New England Journal of Medicine 337(20): 1405-1411 (1997)
Ms	DJ	Schreurs <i>et al.</i> , "A dose-response study with formoterol Turbuhaler™ as maintenance therapy in asthmatic patients," <i>Eur. Respir. J.</i> <u>9:</u> 1679-1683 (1996)

EXAMINER

M

DATE CONSIDERED

05/13/-2

FORM PTO-1449 (Modified)	ATTY. DOCKET NO. 18025-1014	SERIAL NO. 09/887,496
LIST OF PATENTS AND PUBLICATIONS FOR APPLICANT'S INFORMATION DISCLOSURE	APPLICANT Banerjee, Partha S.	
STATEMENT	FILING DATE June 22, 2001	GROUP 1617

OTHER ART (Including Author, Title, Date, Pertinent Pages, Etc.)

M	DK	Seldon <i>et al.</i> , "Albuterol Does Not Antagonize the Inhibitory Effect of Dexamethasone on Monocyte Cytokine Release," <i>Am. J. Respir. Crit. Care Med.</i> <u>157:</u> 803-809 (1998)	
	DL	Silvestri et al., "Fluticasone and salmeterol downregulate in vitro, fibroblast proliferation and ICAM-1 or H-CAM expression," Eur. Respir. J. 18: 139-145 (2001)	
	DM	Sköld <i>et al.</i> , "Glucocorticoids Augment Fibroblast-Mediated Contraction of Collagen Gels by Inhibition of Endogenous PGE Production," <i>Proceedings of the Association of American Physicians</i> 111(3): 249-258 (1999)	
	DN	Stewart et al., "Acute formoterol administration has no argogenic effect in nonasthmatic athletes," Medicine & Science In Sports & Exercise 34(2): 213-217 (2002)	
	DO	Vianna, E.O. and R.J. Martin, "Bronchodilators and Corticosteroids in the Treatment of Asthma," <i>Drugs of Today</i> 34(3): 203-223 (1998)	
	DP	Wilding et al., "Efect of long term treatment with salmeterol on asthma control: a double blind, randomised crossover study," <i>British Medical Journal</i> 314: 1441-1446 (1997)	
W	DQ	Woolcock <i>et al.</i> , "Comparison of Addition of Salmeterol to Inhaled Steroids with Doubling of the Dose of Inhaled Steroids," <i>Am.J. Respir. Crit. Care Med.</i> <u>153:</u> 1481-1488 (1996)	

EXAMINER

24/

DATE CONSIDERED

to / 14/12